Humacyte director granted options on 80,000 shares

Humacyte, Inc. reported that director John Philip Bamforth received a grant of stock options covering 80,000 shares of common stock.

Rhea-AI Filing Summary

Humacyte, Inc. reported that director John Philip Bamforth received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036. Following this grant, he holds 80,000 options directly.

The footnote explains that 25% of the options become exercisable on June 11, 2027, with the remaining portion vesting in equal monthly installments (1/48 of the grant) on the 11th of each month through June 11, 2030. This is a compensation-related award rather than an open-market purchase.

Insider Trade Summary

Grant/Award: 80,000 shares

Grant/Award 1 txn

Insider Bamforth John Philip

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy)	80,000	$0.00	$0.00

Holdings After Transaction: Stock Options (right to buy) — 80,000 contracts (Direct)

Footnotes (1)

1. F1. The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.

Key Figures

Options granted: 80,000 options Exercise price: $1.08 per share Expiration date: June 11, 2036 +3 more

6 metrics

Options granted 80,000 options Stock options (right to buy) granted to director

Exercise price $1.08 per share Exercise price of stock options

Expiration date June 11, 2036 Option expiration

Post-grant option holdings 80,000 options Total derivative securities following transaction

Initial vesting date June 11, 2027 First 25% of options become exercisable

Monthly vesting fraction 1/48 of grant Vests monthly from June 11, 2027 to June 11, 2030

Key Terms

Stock Options (right to buy), Grant, award, or other acquisition, exercise price, Common Stock, +1 more

5 terms

Stock Options (right to buy) financial

"security_title: "Stock Options (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price of $1.0800 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

exercisable financial

"The first 25% of the option becomes exercisable on June 11, 2027"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Humacyte (HUMA) report for John Philip Bamforth?

Humacyte reported a compensation-related grant of stock options to director John Philip Bamforth for 80,000 shares of common stock. The options give him the right to buy shares at a fixed price in the future, subject to a multi-year vesting schedule.

How many Humacyte (HUMA) stock options were granted in this Form 4?

The Form 4 shows a grant of stock options covering 80,000 shares of Humacyte common stock. These options were awarded at no upfront cost and provide the right to purchase shares at a preset exercise price if and when they vest.

What is the exercise price and expiration date of the Humacyte (HUMA) options granted?

The granted options have an exercise price of $1.08 per share and expire on June 11, 2036. This means the director can choose to buy shares at $1.08 before that expiration date, but only for options that have vested.

What is the vesting schedule for the 80,000 Humacyte (HUMA) stock options?

According to the footnote, 25% of the options vest on June 11, 2027. After that, 1/48 of the total grant vests monthly on the 11th of each month through June 11, 2030, creating a gradual, time-based vesting pattern.

Is this Humacyte (HUMA) Form 4 transaction an open-market purchase or a grant?

The transaction is classified as a grant or award acquisition, not an open-market purchase. The options were awarded at a price of $0.00 per option, with an exercise price of $1.08 per share, reflecting standard equity-based director compensation.

How many Humacyte (HUMA) options does John Philip Bamforth hold after this transaction?

After this grant, John Philip Bamforth holds 80,000 stock options directly. The Form 4 indicates this total in the "following transaction" field, and there are no additional derivative positions listed in the derivative summary section of the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 05:52 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bamforth John Philip

(Last) (First) (Middle)

2525 EAST NORTH CAROLINA HIGHWAY 54

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Humacyte, Inc. [ HUMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$1.08	06/11/2026		A		80,000		(1)	06/11/2036	Common Stock	80,000	$0	80,000	D

Explanation of Responses:

1. The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.

	/s/ John Philip Bamforth by Dale A. Sander as Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)